SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
Shares of Pfizer Inc. PFE slid 1.20% to $26.42 Wednesday, on what proved to be an all-around mixed trading session for the ...
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam Feuerstein writes.
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Equities researchers at Zacks Research raised their Q3 2025 earnings estimates for Pfizer in a report issued on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
We recently compiled a list of the Jim Cramer Remembers COVID-19 & Discusses These 11 Stocks. In this article, we are going ...